Beta PRRT → alpha PRRT
When lutetium radioligand therapy stops working, alpha-emitting versions can still control the disease.
ALPHAMEDIX-02 PRRT-exposed cohort: ~83% progression-free at 18 months; ACTION-1 is the randomised test of 225Ac-DOTATATE after 177Lu.
Pages like this
not linked directly; found by shared links- PairingBeta radioligand → alpha radioligand
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyRadioMedix
Shares 212Pb-DOTAMTATE, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyPerspective Therapeutics
Shares Alpha vs beta emitters, Targeted alpha therapy, Neuroendocrine tumours.
- ProductActinium-225 DOTATATE
Shares ACTION-1, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- TechnologyPeptide receptor radionuclide therapy (PRRT)
Shares ALPHAMEDIX-02, 212Pb-DOTAMTATE, Lutetium-177 dotatate, Targeted alpha therapy.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Alpha vs beta emitters, Targeted alpha therapy, Neuroendocrine tumours.